Journal
METABOLIC BRAIN DISEASE
Volume 22, Issue 3-4, Pages 389-405Publisher
SPRINGER/PLENUM PUBLISHERS
DOI: 10.1007/s11011-007-9060-7
Keywords
branched-chain amino acids; bromocriptine; hepatic cirrhosis; hepatic encephalopathy; non-absorbable antibiotics; non-absorbable disaccharides; ornithine aspartate; sodium benzoate; treatment; zinc
Categories
Ask authors/readers for more resources
Current recommendations for the treatment of hepatic encephalopathy are based, to a large extent, on open or uncontrolled trials, undertaken in very small numbers of patients. In consequence, there is ongoing discussion as to whether the classical approach to the treatment of this condition, which aims at reducing ammonia production and absorption using either non-absorbable disaccharides and/or antibiotics, should be revisited, modified or even abandoned. Pros and cons of present therapeutic strategies and possible future developments were discussed at the fourth International Hannover Conference on Hepatic Encephalopathy held in Dresden in June 2006. The content of this discussion is summarized.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available